

December 24, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Appointment of Executive Vice President, Corporate Officer and COO

TOKYO, December 24, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo) today announced that the appointment of Dr. Hirotaka Ito as Executive Vice President, Corporate Officer and Chief Operating Officer (“COO”) was approved by the Company’s board of directors at a meeting of the board held on December 24, 2021.

Appointment of Executive Vice President, Corporate Officer and COO

In the current fiscal year, the Company has set obtaining profitability as the most important management goal, and has advanced the global expansion of our business through initiating full-scale operation of our US subsidiary, SymBio Pharma USA, Inc. To further strengthen our corporate management, the Company will appoint Dr. Hirotaka Ito as Executive Vice President, Corporate Officer and COO effective as of February 1, 2022. Dr. Ito will supervise the sales, the product portfolio, and other key corporate functions, and will be responsible for maintaining profitability and promoting further globalization of the business.

Statement from Dr. Ito: "I join the Company at an important time as it enters its second inauguration after 15 years in business. I am determined to continue our mission since the Company’s founding, which is to provide pharmaceutical products to satisfy unmet medical need, and to work as part of a company-wide effort to improve corporate value by further benefit patients, medical professionals, and all stakeholders."

Statement from Fuminori Yoshida, President and CEO of SymBio: "We welcome Dr. Ito, who has many years of experience in pharmaceutical research, sales, marketing, and commercial operations in Japan and overseas, as well as a proven track record of managing business globally and extensive network. As a member of the management team, he will help transform the Company into a global specialty pharma."

1. Appointment of Corporate Officer

Name	Title
Hirotaka Ito	Executive Vice President, Corporate Officer and COO

2. Date of Appointment: February 1, 2022

3. Profile of the newly appointed Corporate Officer

April 1994	Joined Chugai Pharmaceutical Co, Ltd.
January 2002	Researcher, Research Center for Advanced Science and Technology, University of Tokyo
March 2008	Head of Marketing Planning Department, GE Healthcare Japan Co., Ltd.
October 2012	Director of Strategic Marketing, GE Healthcare Asia Pacific
January 2016	Head of Headquarters Sales, GE Healthcare Japan Co., Ltd.
October 2017	President of Tecan Japan Co., Ltd. (will resign on January 31, 2022)
April 2021	Professor, Graduate School of Management, Globis University (Current)

[Contact]

Investor Relations, Administrative Division

Tel: +81(0)3 5472 1125